Tadalafil in patients on antihypertensive medications: Does safety remain an issue?
Abstract
The paper by Kloner and associates published in this issue of the Journal handles an exciting topic in the hypertension community; the safety of tadalafil in patients with erectile dysfunction (ED) and/or benign prostatic hyperplasia (BPH) concerning major adverse cardiovascular events (MACE) and hypotension-related treatment-emergent adverse events (TEAE).1 This pooled analysis of 22 825 patients from 72 Phase II-IV studies on patients with ED and BPH demonstrated the considerable safety of tadalafil in all of the subgroups examined, with the exception of the as-needed indication in ED patients without concomitant antihypertensive medication intake.1 The worldwide burden of ED is believed to be high owing to the increased life expectancy.2 However, it cannot be estimated appropriately due to the differences in the sensitivity of screening methods applied across the studies. Other than its detrimental role in the quality of life of male individuals, ED is widely regarded as a risk factor associated with cardiovascular morbidity and mortality.2 At the same time, ED frequently coexists with BPH and is also linked to incident dementia.2 ED shares common pathophysiologic mechanisms (low-grade inflammation, oxidative stress, endothelial dysfunction, thrombosis-fibrinolysis imbalance) and risk factors (age, arterial hypertension, diabetes mellitus, smoking, hypercholesterolemia, obesity) with cardiovascular diseases (Figure 1).3 Moreover, the prominent prevalence of arterial…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.